ketorolac has been researched along with Disease Models, Animal in 49 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase." | 7.83 | The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. ( Corr, M; McQueen, J; Park, HJ; Sandor, K; Svensson, CI; Woller, SA; Yaksh, TL, 2016) |
| "The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits." | 7.74 | Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| "We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 7.70 | Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998) |
| " This study used a rabbit model of hearing loss in experimental pneumococcal meningitis to evaluate the therapeutic effect of two anti-inflammatory agents, dexamethasone and ketorolac, coadministered with ampicillin." | 7.70 | Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac. ( Bhatt, SM; Burkard, RF; Merchant, SN; Nadol, JB; Rappaport, JM, 1999) |
| "To determine in rabbits whether periocular injection of ketorolac tromethamine effectively delivers the drug to the eye and, if so, whether this is efficacious in the treatment of experimental uveitis." | 7.69 | Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. ( Fiscella, RG; Rabiah, PK; Tessler, HH, 1996) |
| "Treatment with morphine (1mg/kg, s." | 5.38 | Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. ( Fujita, I; Kita, Y; Okumura, T; Sakakibara, A, 2012) |
| " Because some non-steroidal anti-inflammatory drugs (NSAIDs) are structural analogs of prostaglandins and NSAIDs attenuate heat nociception and mechanical allodynia in models of inflammatory and neuropathic pain, we investigated whether three widely used NSAIDs (diclofenac, ketorolac, and xefocam) affect thermal and mechanical hyperalgesia following the activation of TRPA1 and TRPV1 channels." | 3.88 | Non-steroidal anti-inflammatory drugs attenuate agonist-evoked activation of transient receptor potential channels. ( Gurtskaia, G; Nozadze, I; Tsagareli, MG; Tsiklauri, N, 2018) |
| "Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase." | 3.83 | The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation. ( Corr, M; McQueen, J; Park, HJ; Sandor, K; Svensson, CI; Woller, SA; Yaksh, TL, 2016) |
| "Topical fluorometholone caused suppression of inflammatory cytokine expression on the ocular surface in the Botulium toxin B-induced murine dry eye model, while topical NSAIDs demonstrated no clearly beneficial effects." | 3.78 | Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. ( Chuck, RS; Zhang, C; Zhu, L, 2012) |
| "The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits." | 3.74 | Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. ( El-Gohary, AA; El-Hossary, GG; El-Shazly, AH; El-Shazly, LH, 2008) |
| "Caffeine potentiation of ketorolac-induced antinociception in the pain-induced functional impairment model in rats was assessed." | 3.70 | Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia. ( Aguirre-Bañuelos, P; Castañeda-Hernández, G; Granados-Soto, V; López-Muñoz, FJ, 1999) |
| " This study used a rabbit model of hearing loss in experimental pneumococcal meningitis to evaluate the therapeutic effect of two anti-inflammatory agents, dexamethasone and ketorolac, coadministered with ampicillin." | 3.70 | Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac. ( Bhatt, SM; Burkard, RF; Merchant, SN; Nadol, JB; Rappaport, JM, 1999) |
| "We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain." | 3.70 | Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998) |
| "The therapeutic utility of cyclooxygenase (CO) inhibitors, such as ketorolac, in reducing the inflammatory events associated with allergic conjunctivitis is not unexpected since prostanoids (PG) elicit conjunctival redness (PGD2, PGE2, PGF2 alpha), edema (PGD2, TxA2), eosinophil infiltration (PGD2, PGJ2) and mucous cell discharge (PGD2, PGJ2, TxA2)." | 3.69 | The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. ( Hawley, SB; Joseph, R; Merlino, GF; Nieves, AL; Spada, CS; Woodward, DF, 1995) |
| "To determine in rabbits whether periocular injection of ketorolac tromethamine effectively delivers the drug to the eye and, if so, whether this is efficacious in the treatment of experimental uveitis." | 3.69 | Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. ( Fiscella, RG; Rabiah, PK; Tessler, HH, 1996) |
| "A mouse model of endometriosis recurrence caused by spillage and dissemination was first established using 24 female Balb/c mice." | 1.62 | Preoperative and perioperative intervention reduces the risk of recurrence of endometriosis in mice caused by either incomplete excision or spillage and dissemination. ( Chen, Y; Guo, SW; Liu, X, 2021) |
| "Although current neuropathic pain treatment guidelines do not recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), whether NSAIDs can serve as a useful adjuvant to conventional multimodal therapy remains unclear." | 1.51 | Synergistic symptom-specific effects of ketorolac-tramadol and ketorolac-pregabalin in a rat model of peripheral neuropathy. ( Cheng, YT; Huang, YH; Lin, FS; Lin, WY; Sun, WZ; Yen, CT, 2019) |
| " Both alone and in combination with ketorolac; S." | 1.46 | Synergistic antinociceptive interaction of Syzygium aromaticum or Rosmarinus officinalis coadministered with ketorolac in rats. ( Aguilar-Mariscal, H; Beltrán-Villalobos, KL; Déciga-Campos, M; González-Trujano, ME; López-Muñoz, FJ; Martínez-Salazar, MF; Ramírez-Cisneros, MLÁ; Rios, MY, 2017) |
| "Ketorolac treatments were administered either 1 week before optic nerve crush (pre-ONC) or right after the ONC (simultaneous)." | 1.43 | Ketorolac Administration Attenuates Retinal Ganglion Cell Death After Axonal Injury. ( Agudo-Barriuso, M; Bravo-Osuna, I; Herrero-Vanrell, R; Molina-Martínez, I; Nadal-Nicolás, FM; Rodriguez-Villagra, E; Sobrado-Calvo, P; Vidal-Sanz, M; Villegas-Pérez, MP, 2016) |
| "Eighteen (90%) wounds in the saline-chitosan group and 11 (55%) wounds in the saline-gauze group were healed." | 1.42 | Locally Delivered Nonsteroidal Antiinflammatory Drug: A Potential Option for Heterotopic Ossification Prevention. ( Hsu, JR; Noel, SP; Rathbone, CR; Rivera, JC; Wenke, JC, 2015) |
| "Treatment with morphine (1mg/kg, s." | 1.38 | Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. ( Fujita, I; Kita, Y; Okumura, T; Sakakibara, A, 2012) |
| "Ketorolac is a non-selective NSAID which, at low doses, has a preferential COX-1 inhibitory effect and etoricoxib is a new selective COX-2 inhibitor." | 1.36 | Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. ( Fracon, RN; Lamano, T; Moris, IC; Teófilo, JM, 2010) |
| "Paw inflammation was induced with 3% carrageenan and was measured with a plethysmometer at 30 minutes and 4, 8, and 24 hours after intraperitoneal injection." | 1.36 | Evaluation of the anti-inflammatory effects of ellagic acid. ( Corbett, S; Daniel, J; Drayton, R; Field, M; Garrett, N; Steinhardt, R, 2010) |
| "Eyes treated with ketorolac and diclofenac demonstrated reduced aqueous leucocyte concentrations of 62% and 64% respectively, compared with untreated controls (p<0." | 1.35 | Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ( Barañano, DE; Durairaj, C; Edelhauser, HF; Handa, JT; Kim, SJ; Kompella, UB, 2009) |
| "Ketorolac is a nonopioid, anti-inflammatory drug commonly used for postoperative analgesia." | 1.35 | The effects of postoperative ketorolac on wound healing in a rat model. ( Eck, JC; Gomez, BA; Yaszemski, MJ, 2009) |
| "A pharmacological model of migraine is described using ultrasound vocalization (USV) of rats following central inflammation-induced sensitization to tactile stimulation." | 1.35 | Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo. ( Martino, G; Perkins, MN, 2008) |
| "Naloxone pretreatment had no effect on the antinociceptive effects of intradermal diclofenac, ketorolac, lysine acetyl salicylate, and sodium salicylate." | 1.34 | The local antinociceptive actions of nonsteroidal antiinflammatory drugs in the mouse radiant heat tail-flick test. ( Deveci, MS; Dogrul, A; Gul, H; Gülmez, SE; Ossipov, MH; Porreca, F; Tulunay, FC, 2007) |
| "Pain is the most prominent feature of IC and current therapies provide limited relief." | 1.34 | Pharmacological validation of a model of cystitis pain in the mouse. ( Leventhal, L; Piesla, M; Wantuch, C, 2007) |
| "Ketorolac is a non-steroidal anti-inflammatory drug." | 1.34 | Ketorolac-dextran conjugates: synthesis, in vitro and in vivo evaluation. ( Chaturvedi, SC; Trivedi, P; Vyas, S, 2007) |
| "Bone cancer pain is mostly associated with an inflammatory response dominated by local activation of osteoclasts and by astrogliosis in the spinal cord." | 1.33 | The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. ( Beitz, A; Eikmeier, L; Fike, JR; Jasmin, L; Ohara, PT; Tien, DA; Vit, JP; Wilcox, GL, 2006) |
| "Lipopolysaccharide (LPS)-induced hyperalgesia and the role of cyclooxygenase (COX) isoforms in acute and chronic nociceptive assays have been well established." | 1.33 | Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test. ( Kulkarni, SK; Padi, SS, 2005) |
| "Treatment of postsurgical pain is a major use of analgesics, particularly after abdominal surgery." | 1.32 | Effects of laparotomy on spontaneous exploratory activity and conditioned operant responding in the rat: a model for postoperative pain. ( Buechler, NL; Crews, JC; Eisenach, JC; Kahn, W; Martin, TJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (18.37) | 18.2507 |
| 2000's | 17 (34.69) | 29.6817 |
| 2010's | 21 (42.86) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Asirvatham-Jeyaraj, N | 1 |
| Jones, AD | 1 |
| Burnett, R | 1 |
| Fink, GD | 1 |
| Chen, Y | 1 |
| Liu, X | 1 |
| Guo, SW | 1 |
| Beltrán-Villalobos, KL | 1 |
| Déciga-Campos, M | 1 |
| Aguilar-Mariscal, H | 1 |
| González-Trujano, ME | 1 |
| Martínez-Salazar, MF | 1 |
| Ramírez-Cisneros, MLÁ | 1 |
| Rios, MY | 1 |
| López-Muñoz, FJ | 3 |
| Tsagareli, MG | 1 |
| Nozadze, I | 1 |
| Tsiklauri, N | 1 |
| Gurtskaia, G | 1 |
| Pezhouman, A | 1 |
| Cao, H | 1 |
| Fishbein, MC | 1 |
| Belardinelli, L | 1 |
| Weiss, JN | 1 |
| Karagueuzian, HS | 1 |
| Moradi, A | 1 |
| Kheirollahkhani, Y | 1 |
| Fatahi, P | 1 |
| Abdollahifar, MA | 1 |
| Amini, A | 1 |
| Naserzadeh, P | 1 |
| Ashtari, K | 1 |
| Ghoreishi, SK | 1 |
| Chien, S | 1 |
| Rezaei, F | 1 |
| Fridoni, M | 1 |
| Bagheri, M | 1 |
| Taheri, S | 1 |
| Bayat, M | 1 |
| Cerreta, AJ | 1 |
| Masterson, CA | 1 |
| Lewbart, GA | 1 |
| Dise, DR | 1 |
| Papich, MG | 1 |
| Schiegerl, LJ | 1 |
| Karttunen, AJ | 1 |
| Klein, W | 1 |
| Fässler, TF | 1 |
| Persson, I | 1 |
| Halim, J | 1 |
| Lind, H | 1 |
| Hansen, TW | 1 |
| Wagner, JB | 1 |
| Näslund, LÅ | 1 |
| Darakchieva, V | 1 |
| Palisaitis, J | 1 |
| Rosen, J | 1 |
| Persson, POÅ | 1 |
| Lin, WY | 1 |
| Cheng, YT | 1 |
| Huang, YH | 1 |
| Lin, FS | 1 |
| Sun, WZ | 1 |
| Yen, CT | 1 |
| Cappello, T | 1 |
| Nuelle, JA | 1 |
| Katsantonis, N | 1 |
| Nauer, RK | 1 |
| Lauing, KL | 1 |
| Jagodzinski, JE | 1 |
| Callaci, JJ | 1 |
| Rivera, JC | 1 |
| Hsu, JR | 1 |
| Noel, SP | 1 |
| Wenke, JC | 1 |
| Rathbone, CR | 1 |
| López-Canul, M | 1 |
| Comai, S | 1 |
| Domínguez-López, S | 1 |
| Granados-Soto, V | 3 |
| Gobbi, G | 1 |
| Park, HJ | 1 |
| Sandor, K | 1 |
| McQueen, J | 1 |
| Woller, SA | 1 |
| Svensson, CI | 1 |
| Corr, M | 1 |
| Yaksh, TL | 1 |
| Nadal-Nicolás, FM | 1 |
| Rodriguez-Villagra, E | 1 |
| Bravo-Osuna, I | 1 |
| Sobrado-Calvo, P | 1 |
| Molina-Martínez, I | 1 |
| Villegas-Pérez, MP | 1 |
| Vidal-Sanz, M | 1 |
| Agudo-Barriuso, M | 1 |
| Herrero-Vanrell, R | 1 |
| Zapata-Morales, JR | 1 |
| Aragon-Martinez, OH | 1 |
| Adriana Soto-Castro, T | 1 |
| Alonso-Castro, ÁJ | 1 |
| Castañeda-Santana, DI | 1 |
| Isiordia-Espinoza, MA | 2 |
| Barreras-Espinoza, I | 1 |
| Soto-Zambrano, JA | 1 |
| Serafín-Higuera, N | 1 |
| Zapata-Morales, R | 1 |
| Alonso-Castro, Á | 1 |
| Bologna-Molina, R | 1 |
| El-Shazly, AH | 1 |
| El-Gohary, AA | 1 |
| El-Shazly, LH | 1 |
| El-Hossary, GG | 1 |
| Scarlett, JM | 1 |
| Zhu, X | 1 |
| Enriori, PJ | 1 |
| Bowe, DD | 1 |
| Batra, AK | 1 |
| Levasseur, PR | 1 |
| Grant, WF | 1 |
| Meguid, MM | 1 |
| Cowley, MA | 1 |
| Marks, DL | 1 |
| Barañano, DE | 1 |
| Kim, SJ | 4 |
| Edelhauser, HF | 1 |
| Durairaj, C | 1 |
| Kompella, UB | 1 |
| Handa, JT | 1 |
| Eck, JC | 1 |
| Gomez, BA | 1 |
| Yaszemski, MJ | 1 |
| Toma, HS | 3 |
| Barnett, JM | 2 |
| Penn, JS | 2 |
| Corbett, S | 1 |
| Daniel, J | 1 |
| Drayton, R | 1 |
| Field, M | 1 |
| Steinhardt, R | 1 |
| Garrett, N | 1 |
| Sokolov, AY | 1 |
| Lyubashina, OA | 1 |
| Panteleev, SS | 1 |
| Chizh, BA | 1 |
| Fracon, RN | 1 |
| Teófilo, JM | 1 |
| Moris, IC | 1 |
| Lamano, T | 1 |
| Dong, L | 1 |
| Guarino, BB | 1 |
| Jordan-Sciutto, KL | 1 |
| Winkelstein, BA | 1 |
| Fujita, I | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Kita, Y | 1 |
| Zhu, L | 1 |
| Zhang, C | 1 |
| Chuck, RS | 1 |
| Jones, AE | 1 |
| Watts, JA | 1 |
| Debelak, JP | 1 |
| Thornton, LR | 1 |
| Younger, JG | 1 |
| Kline, JA | 1 |
| Ma, W | 1 |
| Eisenach, JC | 3 |
| Martin, TJ | 2 |
| Buechler, NL | 1 |
| Kahn, W | 1 |
| Crews, JC | 1 |
| Zhang, Y | 1 |
| Buechler, N | 1 |
| Conklin, DR | 1 |
| Padi, SS | 1 |
| Kulkarni, SK | 1 |
| Vit, JP | 1 |
| Ohara, PT | 1 |
| Tien, DA | 1 |
| Fike, JR | 1 |
| Eikmeier, L | 1 |
| Beitz, A | 1 |
| Wilcox, GL | 1 |
| Jasmin, L | 1 |
| Dunbar, SA | 1 |
| Karamian, I | 1 |
| Zhang, J | 1 |
| Gerstenfeld, LC | 1 |
| Al-Ghawas, M | 1 |
| Alkhiary, YM | 1 |
| Cullinane, DM | 1 |
| Krall, EA | 1 |
| Fitch, JL | 1 |
| Webb, EG | 1 |
| Thiede, MA | 1 |
| Einhorn, TA | 1 |
| Dogrul, A | 1 |
| Gülmez, SE | 1 |
| Deveci, MS | 1 |
| Gul, H | 1 |
| Ossipov, MH | 1 |
| Porreca, F | 1 |
| Tulunay, FC | 1 |
| Hsieh, YC | 1 |
| Cheng, H | 1 |
| Chan, KH | 1 |
| Chang, WK | 1 |
| Liu, TM | 1 |
| Wong, CS | 1 |
| Wantuch, C | 1 |
| Piesla, M | 1 |
| Leventhal, L | 1 |
| Vyas, S | 1 |
| Trivedi, P | 1 |
| Chaturvedi, SC | 1 |
| Martino, G | 1 |
| Perkins, MN | 1 |
| Woodward, DF | 1 |
| Nieves, AL | 1 |
| Hawley, SB | 1 |
| Joseph, R | 1 |
| Merlino, GF | 1 |
| Spada, CS | 1 |
| Rabiah, PK | 1 |
| Fiscella, RG | 1 |
| Tessler, HH | 1 |
| Chávez, E | 1 |
| Téllez, F | 1 |
| Pichardo, J | 1 |
| Milán, R | 1 |
| Cuéllar, A | 1 |
| Carbajal, K | 1 |
| Cruz, D | 1 |
| De Winter, BY | 1 |
| Boeckxstaens, GE | 1 |
| De Man, JG | 1 |
| Moreels, TG | 1 |
| Herman, AG | 1 |
| Pelckmans, PA | 1 |
| Rappaport, JM | 1 |
| Bhatt, SM | 1 |
| Burkard, RF | 1 |
| Merchant, SN | 1 |
| Nadol, JB | 1 |
| Ventura, R | 1 |
| Díaz, I | 1 |
| Fernández-Guasti, A | 1 |
| Tost, D | 1 |
| Cabré, F | 1 |
| Mauleón, D | 1 |
| Jett, MF | 1 |
| Ramesha, CS | 1 |
| Brown, CD | 1 |
| Chiu, S | 1 |
| Emmett, C | 1 |
| Voronin, T | 1 |
| Sun, T | 1 |
| O'Yang, C | 1 |
| Hunter, JC | 1 |
| Eglen, RM | 1 |
| Johnson, RM | 1 |
| Aguirre-Bañuelos, P | 1 |
| Castañeda-Hernández, G | 1 |
| Martin, GJ | 1 |
| Boden, SD | 1 |
| Titus, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Toradol on Post-operative Foot and Ankle Healing[NCT03727048] | Phase 4 | 128 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial[NCT04895280] | Phase 4 | 400 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial[NCT04115644] | Phase 4 | 82 participants (Actual) | Interventional | 2017-05-01 | Terminated (stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain as measured by the Visual Analog Scale after first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - immediately after the injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.197 |
| Group 2 (Ketorolac) | 3.577 |
| Group 3 (Kenalog) | 3.677 |
Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - pre-injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 5.77 |
| Group 2 (Ketorolac) | 4.57 |
| Group 3 (Kenalog) | 4.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 2.347 |
| Group 2 (Ketorolac) | 2.837 |
| Group 3 (Kenalog) | 2.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 1
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.397 |
| Group 2 (Ketorolac) | 3.7 |
| Group 3 (Kenalog) | 3.257 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 12
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.447 |
| Group 2 (Ketorolac) | 1.417 |
| Group 3 (Kenalog) | 2.027 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.57 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 4
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.317 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 6
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.357 |
| Group 2 (Ketorolac) | 2.757 |
| Group 3 (Kenalog) | 2.687 |
49 other studies available for ketorolac and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Brain Prostaglandin D2 Increases Neurogenic Pressor Activity and Mean Arterial Pressure in Angiotensin II-Salt Hypertensive Rats.
Topics: Angiotensin II; Animals; Arterial Pressure; Biomarkers; Brain; Chromatography, Liquid; Cyclooxygenas | 2019 |
Preoperative and perioperative intervention reduces the risk of recurrence of endometriosis in mice caused by either incomplete excision or spillage and dissemination.
Topics: Animals; Aprepitant; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Diterpen | 2021 |
Synergistic antinociceptive interaction of Syzygium aromaticum or Rosmarinus officinalis coadministered with ketorolac in rats.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; Female; Herb-Drug Interactions; Ketorol | 2017 |
Non-steroidal anti-inflammatory drugs attenuate agonist-evoked activation of transient receptor potential channels.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Diclofenac; Disease Models, | 2018 |
Topics: Analgesia; Analgesics; Analysis of Variance; Animals; Bacteria; Body Weight; Chromatography, High Pr | 2018 |
Synergistic symptom-specific effects of ketorolac-tramadol and ketorolac-pregabalin in a rat model of peripheral neuropathy.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Ketorolac; Male; Meloxic | 2019 |
Ketorolac administration does not delay early fracture healing in a juvenile rat model: a pilot study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Disease Models, Animal; F | 2013 |
Locally Delivered Nonsteroidal Antiinflammatory Drug: A Potential Option for Heterotopic Ossification Prevention.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Prolife | 2015 |
Antinociceptive properties of selective MT(2) melatonin receptor partial agonists.
Topics: Acetamides; Acetaminophen; Analgesics; Aniline Compounds; Animals; Behavior, Animal; Brain; Disease | 2015 |
The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation.
Topics: Amines; Analgesics; Animals; Arthritis; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapen | 2016 |
Ketorolac Administration Attenuates Retinal Ganglion Cell Death After Axonal Injury.
Topics: Animals; Axons; Axotomy; Cell Survival; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; K | 2016 |
Isobolographic Analysis of the Interaction Between Tapentadol and Ketorolac in a Mouse Model of Visceral Pain.
Topics: Acetic Acid; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, A | 2016 |
The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Facial Pain; | 2017 |
Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits.
Topics: Administration, Topical; Animals; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2008 |
Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation.
Topics: Agouti-Related Protein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arcuate Nucleus of Hypotha | 2008 |
Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Diclofenac; | 2009 |
The effects of postoperative ketorolac on wound healing in a rat model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Ketorolac; Male; Postopera | 2009 |
Inhibition of choroidal neovascularization by intravitreal ketorolac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capillary Permeability; Choroidal Neovascularizati | 2010 |
Improved assessment of laser-induced choroidal neovascularization.
Topics: Animals; Bruch Membrane; Choroidal Neovascularization; Cyclooxygenase Inhibitors; Disease Models, An | 2010 |
Evaluation of the anti-inflammatory effects of ellagic acid.
Topics: Anesthetics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Disease Models, Animal; | 2010 |
Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Choroidal Neovascularizat | 2010 |
Neurophysiological markers of central sensitisation in the trigeminal pathway and their modulation by the cyclo-oxygenase inhibitor ketorolac.
Topics: Animals; Biomarkers; Cyclooxygenase Inhibitors; Disease Models, Animal; Dura Mater; Electric Stimula | 2010 |
Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Anti-Inflammatory Agents, No | 2010 |
Activating transcription factor 4, a mediator of the integrated stress response, is increased in the dorsal root ganglia following painful facet joint distraction.
Topics: Activating Transcription Factor 4; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac.
Topics: Analgesics, Opioid; Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Hyperalgesia; | 2012 |
Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Botuli | 2012 |
Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat.
Topics: Angiography; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenas | 2003 |
Four PGE2 EP receptors are up-regulated in injured nerve following partial sciatic nerve ligation.
Topics: Animals; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Immunohistochemistry; Keto | 2003 |
Effects of laparotomy on spontaneous exploratory activity and conditioned operant responding in the rat: a model for postoperative pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Conditioning, Operant; Disease | 2004 |
Intrathecal morphine and ketorolac analgesia after surgery: comparison of spontaneous and elicited responses in rats.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Cyclooxygenase Inhibitors; Dise | 2005 |
Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Di | 2005 |
The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception.
Topics: Analgesia; Analgesics, Opioid; Animals; Antineoplastic Agents; Behavior, Animal; Bone Neoplasms; Che | 2006 |
Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-R | 2007 |
Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2007 |
Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2007 |
Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2007 |
Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.
Topics: Animals; Biomechanical Phenomena; Bony Callus; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2007 |
The local antinociceptive actions of nonsteroidal antiinflammatory drugs in the mouse radiant heat tail-flick test.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Dipyrone; Disease | 2007 |
Protective effect of intrathecal ketorolac in spinal cord ischemia in rats: a microdialysis study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Chromatography, High Pressure Liquid; | 2007 |
Pharmacological validation of a model of cystitis pain in the mouse.
Topics: Analgesics; Animals; Behavior, Animal; Cyclophosphamide; Cystitis; Disease Models, Animal; Dose-Resp | 2007 |
Ketorolac-dextran conjugates: synthesis, in vitro and in vivo evaluation.
Topics: Acetic Acid; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Buffers; Carrag | 2007 |
Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diazepam; Diseas | 2008 |
The pruritogenic and inflammatory effects of prostanoids in the conjunctiva.
Topics: Animals; Capillary Permeability; Conjunctiva; Conjunctivitis, Allergic; Cyclooxygenase Inhibitors; D | 1995 |
Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aqueous Humor; Conjunctiva; Disease Models, Animal | 1996 |
On the protection by ketorolac of reperfusion-induced heart damage.
Topics: Analysis of Variance; Animals; Arrhythmias, Cardiac; Blood Pressure; Calcium; Creatine Kinase; Cyclo | 1996 |
Differential effect of indomethacin and ketorolac on postoperative ileus in rats.
Topics: Animals; Disease Models, Animal; Indomethacin; Intestinal Obstruction; Ketorolac; Nitric Oxide; Nitr | 1998 |
Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac.
Topics: Acoustic Stimulation; Ampicillin; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-S | 1999 |
Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Biotransformation; Dise | 1998 |
Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Carrageenan; Cyclo | 1999 |
Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Administration, Topical; Analgesics, Non-Narcotic; Animals; | 1999 |
Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Morphogenetic Protein 2; Bone Morphogenetic P | 1999 |